Granisetron hydrochloride is available in 1-mL single-dose and 4-mL multiple-dose vials containing in each mL the equivalent of granisetron 1 mg and sodium chloride 9 mg.3123; 3124; 3125; 3126 Preservatives and other excipients can vary among products and may include benzyl alcohol,3125 methyl- and propylparaben,3123; 3126 and phenol.3124 Sodium hydroxide and/or hydrochloric acid may have been added to adjust the pH.3123; 3125; 3126 Specific product labeling should be consulted for additional formulation details.
Preservative-free formulations of the 1-mg/mL concentration in 1-mL single-dose vial also are available.3124
Granisetron hydrochloride also is available in 1-mL single-dose vials containing the equivalent of granisetron 0.1 mg and sodium chloride 9 mg.3123; 3124; 3125 Excipients can vary among products.3123; 3124; 3125; 3126 Sodium hydroxide and/or hydrochloric acid may have been added to adjust the pH.3123; 3125; 3126 Specific product labeling should be consulted for additional formulation details.
pH
From 4 to 63123; 3124; 3125 or from 4.4 to 5.3126
Equivalency
Granisetron hydrochloride 1.12 mg provides 1 mg of granisetron.3123; 3124; 3125; 3126
Granisetron hydrochloride may be administered intravenously undiluted over 30 seconds or by intravenous infusion over 5 minutes after dilution with sodium chloride 0.9% or dextrose 5%.3123; 3124; 3125; 3126
Granisetron hydrochloride is a clear, colorless injection.3123; 3124; 3125; 3126 Intact vials should be stored at controlled room temperature and retained in the original carton to protect from light; vials should not be frozen.3123; 3124; 3125; 3126 The unused portion from a single-dose vial should be discarded;3123 the contents of multiple-dose vials should be used within 30 days after initial stopper penetration.3123; 3124; 3125; 3126 Solutions diluted for infusion in sodium chloride 0.9% or dextrose 5% should be prepared at the time of administration, but have been noted to be stable for at least 24 hours when stored at room temperature under normal lighting conditions.3123; 3124; 3125; 3126 Solutions should be visually inspected for particulate matter and discoloration prior to administration.3123; 3124; 3125; 3126
Syringes
Granisetron hydrochloride (SmithKline Beecham) 0.05, 0.07, and 0.1 mg/mL (as granisetron) in sodium chloride 0.9% and in dextrose 5% was repackaged in polypropylene syringes (Sherwood Medical) (closure unspecified). Little or no granisetron hydrochloride loss occurred after 14 days at 5 and 24°C.1968
Granisetron hydrochloride (SmithKline Beecham) 1 mg/mL was repackaged into Plastipak (Becton Dickinson) polypropylene syringes and stored at room temperature exposed to or protected from light and refrigerated at 4°C. Little granisetron hydrochloride loss occurred in 15 days under any of these storage conditions.2149
Central Venous Catheter
Granisetron hydrochloride (SmithKline Beecham) 10 mcg/mL in dextrose 5% was found to be compatible with the ARROWg+ard Blue Plus (Arrow International) chlorhexidine-bearing triple-lumen central catheter. Essentially complete delivery of the drug was found with little or no drug loss occurring. Furthermore, chlorhexidine delivered from the catheter remained at trace amounts with no substantial increase due to the delivery of the drug through the catheter.2335
For a list of references cited in the text of this monograph, search the monograph titled References.